CureVac's CVGBM Cancer Vaccine Induces Promising Immune Responses in Phase 1 Study in Glioblastoma Presented at the ESMO 2024 Congress

• Preliminary immunogenicity results demonstrate induction of cancer antigen-specific T-cell responses in 77% of evaluable patients following CVGBM monotherapy

• 84% of immune responses were de novo, observed in patients without pre-existing
  T-cell activity against encoded cancer antigens

CVGBM was generally well tolerated up to the highest tested dose level of 100 µg with no dose-limiting toxicities

Most common adverse events were mild to moderate systemic reactions such as headache, fever and chills, which resolved within 1-2 days post injection

100 µg was selected as the recommended dose for the dose expansion phase, which recently started enrollment

TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / September 13, 2024 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today presented compelling data from the dose-escalation Part A of its ongoing Phase 1 CVGBM cancer vaccine study in patients with glioblastoma at the European Society for Medical Oncology (ESMO) Congress. The presented data include safety, tolerability and initial immunogenicity data provided for all evaluable patients treated within Part A of the trial with CVGBM dose levels of 12-100 µg. The presentation can be reviewed here.

In this highly aggressive and challenging cancer indication, preliminary immunogenicity results demonstrate that treatment with CVGBM-only following chemo-radiation therapy successfully induces cancer antigen-specific T-cell responses in 77% of evaluable patients. Most notably, within the group of responding patients, 84% of immune responses were generated de novo by the CVGBM vaccination, inducing T-cell activity in patients who had no pre-existing T-cell activity against the encoded antigens. While CD8⁺ T-cells primarily attack and destroy cancer cells, CD4⁺ T-cells play a critical role in coordinating the immune response and supporting the activity of CD8⁺ T-cells over time. The majority of responding patients (69%) showed cancer antigen-specific CD8⁺ responses, 31% of responding patients had CD4⁺ responses and 23% had both a CD8⁺ and a CD4⁺ response.

So handeln Sie das Kursziel

Der Analyst erwartet ein Kursziel von 2,78€, was einem Rückgang von -4,00% zum aktuellen Kurs entspricht. Mit diesen Produkten können Sie die Kurserwartungen des Analysten übertreffen.

 

HSBC Trinkaus & Burkhardt GmbH

 

Alle Partner

Übernehmen

Für Ihre Einstellungen haben wir keine weiteren passenden Produkte gefunden.
Bitte verändern Sie Kursziel, Zeitraum oder Emittent.Alternativ können Sie auch unsere Derivate-Suchen verwenden
Knock-Out-Suche | Optionsschein-Suche | Zertifikate-Suche

WerbungDisclaimer